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Introduction
In certain types of cancer, the activation of kinases is known to have a role in oncogenicity (1) . Therefore, kinase inhibitors are an attractive option for use as cancer chemotherapy (2) . These drugs confer a survival benefit to cancer patients; however, a number of mechanisms of acquired resistance to kinase inhibitors have been reported (3, 4) . For example, gatekeeper mutations that confer resistance to kinase inhibitors frequently occur in EGFR (5, 6) and BCR-ABL (7) .
Metastatic melanoma patients have a very poor prognosis with a median survival time of only 6 to 10 months (8) . The BRAF-V600E mutation occurs in approximately 50% of melanomas, and this mutation is strongly associated with tumorigenicity (8, 9) . the reactivation of the mitogen-activated protein kinase (MAPK) signaling pathway and the activation of the AKT signaling pathway (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
The MEK1-C121S mutation downstream of BRAF is an acquired mutation that has recently been found to confer resistance to vemurafenib (12) . This mutation also confers resistance to the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib (AZD6244) (12) . MEK1-C121S suppresses the MAPK pathway inhibitory activity of vemurafenib and selumetinib (12) . Therefore, to improve the clinical outcome of BRAF-V600E melanomas harboring MEK1-C121S, drugs that further inhibit the MAPK pathway are required.
E6201 is a novel MEK inhibitor that we developed (23) , and a Phase I clinical trial of E6201 is ongoing in advanced solid tumors (Trial registration ID: NCT00794781). The chemical structure of E6201, a derivative of the natural product f152A1, is markedly different from the representative allosteric MEK inhibitors (Fig. 1) . A docking simulation showed that f152A1 binds at the ATP binding site of MEK1 (24) ; therefore, E6201 is also likely to be an ATP-competitive MEK inhibitor with different pharmacological activities than those of allosteric MEK inhibitors. Here, we investigated the use of E6201 as a MEK inhibitor against BRAF-V600E melanoma harboring MEK1-C121S. We show that E6201 is an ATP-competitive MEK inhibitor that has potent growth inhibitory activity in BRAF-V600E melanoma compared with BRAF wild-type (WT) melanoma, although the compound inhibited the MAPK pathway both in BRAF-WT and BRAF-V600E melanoma. Furthermore, we demonstrate that E6201 is effective in a preclinical model against BRAF-V600E melanoma harboring MEK1-C121S and warrants further clinical investigation in a larger setting. 
Materials and Methods

Compounds
Selumetinib and vemurafenib were provided by Wuxi AppTec (Shanghai, China).
Construction of pENTR_L1-MEK1-R5 ENTRY vector
pF1KE0668, a plasmid harboring the coding regions of the full-length MEK1 gene, was purchased from Kazusa DNA Research Institute. The MEK1 coding region was amplified using the following primer set: attB1_MEK1-Fwd.,
attB5r_MEK1-Rev.,
5'-ggggacaacttttgtatacaaagttgtttagacgccagcagcatgggttggtgtgctgggc-3'. PCR reactions were performed in a total volume of 50 μL containing 10 μM of each primer, 0. μg/mL kanamycin. Two att-site sequences and the MEK1 region were checked by sequencing. 
Construction of pCLxIP_MEK1 (WT or C121S)-IRES-hmAG vectors
Cell lines and cell cultures
The human melanoma cell lines HMV-1 and SEKI were obtained from the Japanese Cells were incubated with a serial dilution of the test compounds in complete medium at 37°C for 24 h. Cells were lysed with cell lysis buffer (Cell Signaling Technology) containing 1 mM phenylmethylsulfonyl fluoride. Cellular debris was removed by centrifugation at 15,000 g for 20 min at 4°C. Western blotting was performed as described (25) . Supernatants containing 10 μg of protein were subjected to SDS-PAGE under reducing conditions. The proteins were then transferred onto polyvinylidene fluoride membranes (Millipore) blocked with TBS containing 0.05% Tween-20 and 5% skim milk. The membranes were then probed with the following antibodies:
anti-phospho Erk1/2 (Thr202/Tyr204), anti-ERK1/2 (Cell Signaling Technology), and anti-Cyclin D1 (BD Biosciences). Immunoreactive bands were visualized by detecting chemiluminescence with a ChemiDoc XRS gel imaging system (BIO-RAD).
Cell proliferation assay
Cells (2 × 10 3 cells/100 μL/well) were seeded in 96-well culture plates. After overnight incubation at 37°C under a humidified atmosphere containing 5% CO 2 , various concentrations of each compound were added, and cultured for 3 days. Then, 10
μL of WST-8 reagent (Dojindot) was added to each well, and absorbance was measured at 450 nm by using an Envision multilabel plate reader (Perkinelmer) and compared with a reference measurement at 665 nm.
In vitro MEK1 and MEK2 kinase assay
An ELISA assay kit containing MEK1 and MEK2 recombinant protein was purchased from Carna Biosciences. The assay was performed according to Carna Biosciences' internal protocol. (26), and the protein structure was prepared by using the Maestro software package (Schro dinger). Hydrogen atoms were added and a brief relaxation was performed on each starting structure using the Protein Preparation module in the Maestro software. These coordinates were used for the selumetinib docking simulation. For the E6201 simulation, a MEK1 model was built by using the Prime homology modeling program (27, 28) and the human-ERK2 crystal structure (PDB entry code: 2E14) (29) coordinates as the template structure.
Immunocytochemistry
2) Induced-fit docking simulation
The Induced-Fit Docking (IFD) (30) 
computed based on the GlideScore and a small fraction of the Prime energy by using the following formula: IFD Score = GlideScore + 0.05 Prime energy. 
Results
E6201 is an ATP-competitive MEK1 and MEK2 inhibitor
To determine whether E6201 is an ATP-competitive or -noncompetitive MEK inhibitor, the inhibitory activity of E6201 on MEK1 and MEK2 was evaluated by using a cell-free kinase assay with various concentrations of ATP (Fig. 2) . The IC 50 values of E6201 in the MEK1 cell-free assay were 0.020, 0.12, and 1.4 μM at ATP concentrations of 10, 30, and 100 μM, respectively. The IC 50 values in the MEK2 cell-free assay were 0.028, 0.067, and 0.70 μM at ATP concentrations of 10, 30, and 100 μM, respectively.
The inhibitory activity of E6201 decreased with increasing ATP dose indicating that E6201 is an ATP-competitive MEK1 and MEK2 inhibitor.
Efficacy of E6201 against BRAF-V600E or -WT melanoma
BRAF-V600E melanoma is reported to be more sensitive than BRAF-WT melanoma 
(G361, MDA-MB435, SEKI and A375). The BRAF mutation status of these cell lines was confirmed by DNA sequencing. Cell lines harboring the BRAF-V600E mutation were more sensitive to vemurafenib and selumetinib compared with BRAF-WT cell lines (Fig. 3A) . E6201 also showed potent growth inhibitory activity in BRAF-V600E melanoma cell lines compared with BRAF-WT cell lines.
Next, we examined the MAPK pathway inhibitory activity of E6201 in a BRAF-V600E mutant (A375 and G361) and BRAF-WT melanoma (HMV-1) cell line ( Fig. 3B and Supplementary Fig. S1 ). Vemurafenib inhibited extracellular signal-regulated kinase (ERK) phosphorylation in the BRAF-V600E mutant but not in the BRAF-WT melanoma (Fig. 3B) , whereas selumetinib inhibited ERK phosphorylation in both the BRAF-V600E mutant and the BRAF-WT melanoma.
E6201 also inhibited ERK phosphorylation in both the BRAF-V600E mutant and the BRAF-WT melanoma ( Fig. 3B and Supplementary Fig. S1 ). E6201 inhibited ERK phosphorylation at a lower dose in the BRAF-V600E mutant than in the BRAF-WT melanoma; whereas selumetinib inhibited ERK phosphorylation in the BRAF-V600E mutant at approximately the same dose as in the BRAF-WT melanoma. These results indicate that the growth inhibitory activity of E6201 in melanoma cell lines harboring the BRAF-V600E mutation is mediated via MEK inhibition. 
E6201 effectiveness on cells transiently or constitutively expressing MEK1-C121S
MEK1-C121S point mutation confers resistance to both vemurafenib and selumetinib (12) . E6201 is an ATP-competitive MEK inhibitor that binds to MEK1 or MEK2 differently from allosteric MEK inhibitors. E6201 may therefore be effective against BRAF-V600E melanomas harboring MEK1-C121S.
To assess whether MEK1-C121S confers resistance to E6201 in melanoma cells, we transiently transfected A375 human melanoma cells with a MEK1-C121S-expressing vector. A375 was used because this cell line is reported to harbor the BRAF-V600E mutation and has frequently been used in similar experiments (12, 34) . The presence of the BRAF-V600E mutation in A375 was confirmed by DNA sequencing. After treatment with the test compounds, transfected cells were immunocytochemically stained for Cyclin D1, which is a marker of the cytostatic effect of MAPK inhibitors (32, 35, 36). Only about 10% of cells were transfected with expression vectors in our transfection protocol, so to be able to identify transfected cells, we designed expression vectors for the co-expression of the IRES-dependent Azami-Green and MEK1 genes. Cell Analyzer high-content analysis system. Cyclin D1 expression decreased after treatment with 3.3 μM vemurafenib or 1.1 μM selumetinib in almost all of the Azami-Green-negative cells, but not in all of the Azami-Green-positive cells (Fig. 4A) .
However, Cyclin D1 expression decreased after treatment with 1.1 μM E6201 in both Fig. S2 ). In contrast, the Cyclin D1 expression inhibitory activity of E6201 in Azami-Green-positive (exogenous MEK1-WT or C121S-positive) cells barely changed compared with Azami-Green-negative (exogenous MEK1-WT-or C121S-negative) cells (Fig. 4 and Supplementary Fig. S2 ). Moreover, the same result was obtained by using G361 (Supplementary Fig. S3 ). In A375 and G361, apoptosis was not inducted by MAPK inhibition. (Supplementary Fig. S4 (Fig. 5A) . However, that of E6201 in the MEK1-C121S transfectant was that same as that in the MEK1-WT transfectants (Fig. 5A) . These results indicate that the MEK1-C121S mutation confers resistance to both vemurafenib and selumetinib but not E6201.
Mechanism of acquired vemurafenib and selumetinib resistance and effectiveness of E6201 against MEK1-C121S melanoma
To confirm the mechanism of vemurafenib and selumetinib resistance and the effectiveness of E6201 against MEK1-C121S mutant melanoma, ERK phosphorylation inhibitory activity was assessed in A375 MEK1-WT and -C121S transfectants (Fig. 5B) . 
Discussion
On the basis of its MEK inhibitory activity, E6201 was shown here to be an ATP-competitive MEK inhibitor that is effective against BRAF-V600E melanoma in a preclinical setting. Furthermore, we showed that E6201 is effective in a preclinical model against BRAF-V600E melanoma harboring the MEK1-C121S mutation. Almost all of the MEK inhibitors previously reported are allosteric inhibitors, not ATP-competitive inhibitors (37). Our docking simulation showed that E6201 and selumetinib bind to different sites when they dock with MEK. These results suggest that the inhibitory mode of action of E6201 is different from that of allosteric MEK inhibitors and that E6201 merits further investigation in a clinical setting against both MEK-WT melanomas and melanomas harboring MEK with mutations at the allosteric site.
The MEK1-C121S mutation, which confers resistance to vemurafenib, increases MEK activity independently from BRAF and also confers resistance to the allosteric MEK inhibitor selumetinib (12) . Our docking simulation showed that the MEK1-C121S mutation induced by vemurafenib treatment is located where selumetinib binds with MEK1, but is far from where E6201 binds with MEK1. This may account for the selumetinib resistance in BRAF-V600E melanoma harboring the MEK1-C121S 
mutation. In contrast, E6201 suppressed ERK phosphorylation and inhibited cell growth equivalently in BRAF-V600E melanoma harboring MEK1-C121S and in WT melanoma cells. Thus, this is the first paper showing that E6201 is potentially effective against melanomas with acquired resistance to vemurafenib associated with the MEK1-C121S mutation. Further investigation in a clinical setting in a larger trial is warranted.
Our preclinical data suggest that E6201 warrants further study as a novel and potentially favorable therapeutic approach for melanoma. One option for using We show here that the inhibitory activity of E6201 was higher in BRAF-V600E melanoma than in BRAF-WT melanoma, whereas that of selumetinib in BRAF-V600E was the same as in BRAF-WT. This inhibitory selectivity of E6201 against BRAF-WT and BRAF-V600E may lead to a broader therapeutic window because of its weak activity in BRAF-WT cells.
In conclusion, this preclinical study might lead to support the clinical development of 
